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all 9 patients received rituximab at 2-18 days (4-6 doses)
after diagnosis. Early rituximab ( 7 days) reduced time to
CR (Hb  8 &/or platelets  100): median 13 days (7-49
days) if early rituximab in 4 patients versus 58 days (19-98
days) in 5 without early rituximab. Moreover, an initial
IVIg/corticosteroids/rituximab combination was best (CR 7-
13 days). Four patients ﬂared at 28-393 days but all
achieved CR with further treatment. Drug therapy was well
tolerated whereas 2 of 3 patients who underwent
splenectomy with initial therapy or with relapse had
complications. Eight of 9 AH/ITP patients are alive &
disease free. Seven of them are in CR from AH/ITP at a
median of 30 months (range 9-102) follow-up after AH/ITP
diagnosis whereas one has recurrent AH requiring therapy.
Conclusions: While AH/ITP is infrequent it can have sudden
onset and be life-threatening. The mechanism is likely
transient B-cell immune dysregulation during immunosup-
pression taper, and thus patient monitoring and prompt
recognition during this period are warranted. Early
rituximab treatment is both mandated at presentation in
severe disease and will likely reduce corticosteroid exposure
& could avoid splenectomy.334
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Background: Reactivation of cytomegalovirus (CMV) and
Epstein-Barr virus (EBV) following allogeneic stem cell
transplant occurs in 60-70% and 5-15% of patients
respectively. CMV disease can present as pancytopenia,
disordered liver function, pneumonitis, retinitis or
neurological disorders. EBV reactivation can result in post
transplant lymphoproliferative disorder (PTLD). At risk
patients are monitored using DNA PCR assays and
pre-emptive therapy commenced. The optimum timing for
intervention has not been established.
Methods: We identiﬁed at-risk patients receiving an
allogeneic transplant during the period 2012-2013 from ourinstitutional database and retrospectively collected data
from the electronic and paper records.
Results: Complete data was available for 27 patients. The
diagnoses were AML/MDS (14), ALL (6), CLL (3), CML (1),
aplastic anaemia (1) andmyeloﬁbrosis (1). 26 were at risk for
EBV reactivation and 13 were at risk for CMV reactivation.
5/13 (38%) patients developed CMV reactivation at a median
of 26 days post transplant (range 22-49). The median CMV
DNA peak titre was 3647 IU/ml (range 603-62616). 4/5
patients were treated with valganciclovir and none
developed CMV disease. Valganciclovir was well tolerated
and effective in all cases. 7/26 patients (27%) developed EBV
reactivation after amedian 60 days (range 10-221). 2 patients
(12.5%) developed lymphadenopathy and received rituximab
with a complete response. Two patients developed late onset
recurrent EBV reactivation following treatment with
rituximab. One patient had a rising titre from day +165,
continuing to rise from <137 to 37944 IU/ml on day +494.
The second patient reactivated on day +225 with a titre
continuing to rise to 23693 IU/ml on day +264. Neither
patient was on immunosuppression or has developed clinical
or radiological evidence of PTLD.
Conclusion: CMV reactivation was less frequent than
previously reported and pre-emptive therapy was effective.
It is possible that some patients were treated unnecessarily
although treatment was well tolerated. EBV reactivation
rates were consistent with those previously reported. Two
cases of PTLD highlight the importance of regular EBV titre
monitoring and early treatment. The late re-emergence
of EBV reactivation in patients who are not on immuno-
suppression is not well described in the literature and its
pathogenesis and clinical signiﬁcance may be different from
early reactivation.335
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Background: Disseminated fungal infection is a major cause
of morbidity and mortality in children undergoing HCT.
Anti-fungal prophylaxis with intravenous micafungin has a
distinct advantage over amphotericin-B and oral triazoles
due to its better safety proﬁle, speciﬁcally in terms of hepatic
and renal toxicity, and lack of drug-drug interactions
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Currently, children who receive prophylactic micafungin are
given daily dosing (1mg/kg/dose) or alternate day dosing
(3mg/kg/dose). We hypothesized that higher dose
micafungin (5 mg/kg) every 4 days will provide effective
anti-fungal prophylaxis, and improve patient compliance
(with essentially twice a week dosing regimen).
Objectives: To examinemicafungin PKwhen given at 5mg/kg
dose for anti-fungal prophylaxis to children undergoing HCT.
Methods: Nine children with various hematological, meta-
bolic and immune deﬁciency disorders undergoing HCT
received a single dose of micafungin (5 mg/kg) intravenously
over 1 hour. Dose selection was based on published PK data
in pediatric neutropenia patients (Seibel et al. 2005), our
alternate day micafungin PK study (Mehta et al. 2010), along
with Monte Carlo PK/PD simulation. Blood samples were
drawn around the micafungin infusion and at regular
intervals until 96 hours after. Plasma concentration data
were analyzed by noncompartmental (WinNonlin) and
population PK analysis (NONMEM).
Results:Micafungin at 5 mg/kg dose was well tolerated in all
subjects along with measurable plasma concentrations at 96
hours (Table 1). PK was best described by a 2-compartment
model in all subjects (Figure 1). The mean concentration at
96 hours was 0.11 mg/mL (Range: 0.03-0.26 mg/mL).
Concentrations at the end of the 96 hours remain above
the minimum inhibitory concentration (MIC) of susceptible
fungal pathogens (MIC >0.2 mg/ml) in 1 patient (11%) only.
However, target concentrations were achieved in 7/9 (78%)
patients at the end of 72 hours. When accounted for the
post-antifungal effect, all 9 (100%) patients were in the goal
range at the end of 72 hours.
Conclusion: Our data suggest that although micafungin at 5
mg/kg dosing generates suboptimal levels at the end of 4
days, observed levels at the end of 3 days were in the target
range, to cover susceptible fungal pathogens and provide an
attractive alternative for anti-fungal prophylaxis in children
undergoing HCT.
This study was supported by an unrestricted research grant
from Astellas Pharma US, Inc. The sponsor did not participate in
study design or interpretation of results.Table 1
Micafungin concentrations
Patient At 24 hrs
(mg/ml)
At 48 hrs
(mg/ml)
At 72 hrs
(mg/ml)
At 96 hrs
(mg/ml)
Mean 4.60 1.19 0.34 0.11
SD 1.07 0.36 0.15 0.08
Figure 1. PK proﬁle of micafungin337
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Background: Oral mucositis (OM) is the most debilitating
adverse effect of treatment from patient perspective during
Allogeneic Stem Cell Transplantation (ASCT).The intensity of
the conditioning regimen relates to both incidence & severity
of OM; however no previously published study has analyzed
this relationship. We sought to perform a meta-analysis and
systemic review on the incidence and outcomes of OM in
ASCT patients, and analyze this association.
Methods: A comprehensive search of several databases
(Ovid Medline In-Process & Other Non-Indexed Citations,
Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane CRCT, Ovid
Cochrane DSR and Scopus) from 1990-2014 for studies of OM
in ASCT patients was conducted by an experienced medical
librarian. To avoid ﬁle-drawer bias, professional society
meeting (ASH, EHA, ASBMT, EBMT, AAD) abstracts were
searched. Studies were includedwith strict eligibility - if they
reported the grade & incidence of OM with validated scales,
and provided details of conditioning regimen and Graft-
versus-host-disease (GVHD) prophylaxis (including doses
e.g. methotrexate). Grade of OM was analyzed based on the
WHO or NCI-CTCAE scales. For studies not utilizing these
scales, only overall incidence of OM was reported. Severe
mucositis was deﬁned as either Grade 2-4 or Grade 3-4
depending on the studies' deﬁnition of severity. Cohorts
were analyzed based on regimen intensity i.e. Reduced
Intensity Conditioning (RIC) [including Non-myeloablative]
and Myeloablative (MA).
Results: A total of 624 studies generated from the search
were reviewed. Of the 582 patients in 14 eligible MA regimen
studies, 75.4% experienced any OM, while in 245 patients
reviewed in the 6 eligible RIC regimen studies, 86.1%
experienced any OM (ﬁgures 1&2). A majority of studies
utilized the WHO or NCI-CTCAE scales. Severe OM occurred
in 73.3% of the WHO/NCI graded MA conditioning patients
and 67.8% of WHO/NCI graded RIC conditioned patients.
Other grading scales included in the studies were Oral
Mucositis Index, the Southwest Oncology Group (SWOG)
Criteria, and the Eastern Cooperative Oncology Group
(ECOG) scale. Due to the lack of randomized controlled trials
focusing on OM as the primary outcome variable and
heterogeneity of scales used to measure OM, a meta-analysis
could not be performed; however pooled analysis indicated
signiﬁcant differences in incidence of OM with respect to
different conditioning regimens (ﬁgures 1&2).
Conclusions: To our knowledge, this is the ﬁrst analysis on
OM in ASCT patients and we found that RIC regimens led to a
very high incidence of OM similar to that of MA regimens.
Clinical trials on treatment of OM are lacking emphasizing
the essential need for prospective studies in this arena. A
signiﬁcant variance in the criteria for grading OM
undermines the importance of establishing standard grading
system for OM measurement in future ASCT clinical trials
globally.
